

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yair FELD et al

Serial No.: 09/691,889

Filed: October 20, 2000

For: Nucleic Acid Constructs And Cells, And  
Methods Utilizing Same For Modifying The  
Electrochemical Conductance Of Excitable Tissues

Examiner:



§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Group Art Unit: 1632

Attorney  
Docket: 00/20989

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Sol Sheinbein".

Sol Sheinbein  
Registration No. 25,457

Dated: January 19, 2005



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/691,889
Filing Date	October 20, 2000
First Named Inventor	FELD Yair et al
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	00/20989

Sheet	1	Of	1
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Crystal "Transfer of Genese to Humans: Early Lessons and Obstacles to Success", Science 270: 404-410, 1995.	
	2	Deonarain "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery", Exp. Opin. Ther. Patents 8(1): 53-69, 1988.	
	3	Friedmann "Overcoming the Obstacles to Gene Therapy", Sci Am 276(6): 96-101, 1997.	
	4	Jackowski "Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer", British Journal of Neurosurgery 9(3): 303-17, 1995.	
	5	Sangro et al. "Gene Therapy of Neoplastic Liver Diseases", International Journal of Cell Biology, 35(2): 135-148, 2003. Abstract.	
	6	Bruckner "INGN-201. Introgen Therapeutics", Current Opinion Investigating Drugs, 2(12): 1776-1785, 2001. Abstract.	
	7	Nasz et al. "Recombinant Adenovirus Vectors for Gene Therapy and Clinical Trials", Acta Microbiol. Immunol. Hung, 48(3-4): 323-348, 2001. Abstract.	
	8	Cohen et al. "ONYX-015-Onyx Pharmaceuticals", Current Opinion Investigating Drugs, 2(12): 1770-1775, 2001. Abstract.	
	9	Kirn "Oncolytic Virotherapy for Cancer with Adenovirus D11520 (Onyx-015): Results of Phase I and II Trials", Expert Opinion Biol. Ther., 1(3): 525-538, 2001. Abstract.	
	10	Merritt et al. "Clinical Evaluation of Adenoviral-Mediated P53 Gene Transfer: Review of INGN 201 Studies", Semin. Oncol., 28(Suppl. 16): 105-114, 2001. Abstract.	
	11	Banerjee "Genasense (Genta Inc)" Current Opinion Investig. Drugs, 2(4):574-580, 2001. Abstract.	
Signature			Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Applicant's unique citation designation number (optional). <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.